Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells

Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation

(2018) Wei-Qiang Jia et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

(2018) Zhenyi An et al.   ONCOGENE

Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance

(2018) Yu Shi et al.   Science Translational Medicine

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment

(2017) Stefanie Keller et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma

(2017) Maria J. Williams et al.   Frontiers in Oncology

Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo

(2016) Tae Jin Han et al.   JOURNAL OF NEURO-ONCOLOGY

Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells

(2016) Viviane Rösner Almeida et al.   MOLECULAR NEUROBIOLOGY

A guide for the analysis of long-term population growth in cancer

(2016) Andrew O. Silva et al.   TUMOR BIOLOGY

BIS-mediated STAT3 stabilization regulates glioblastoma stem cell-like phenotypes

(2016) Chang-Nim Im et al.   Oncotarget

PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals

(2016) Carlo Cenciarelli et al.   Oncotarget

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

(2015) Gabriele Greve et al.   BMC CANCER

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

(2015) Alessandra Leone et al.   FREE RADICAL BIOLOGY AND MEDICINE

Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition

(2015) Katrin Liffers et al.   Targeted Oncology

Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells

(2014) Felipe de Almeida Sassi et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma

(2013) Qi-Wen Fan et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line

(2013) SEOK-HO MOON et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor κB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway

(2013) Jo Meagan Garner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of Stat3 in glioblastoma multiforme

(2013) Rodney B. Luwor et al.   JOURNAL OF CLINICAL NEUROSCIENCE

STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

(2012) Shinji Kohsaka et al.   MOLECULAR CANCER THERAPEUTICS

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines

(2011) Estefanía Carrasco-García et al.   EXPERIMENTAL CELL RESEARCH

Current and emerging molecular targets in glioma

(2010) Rafael Roesler et al.   Expert Review of Anticancer Therapy

LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model

(2009) B Fuh et al.   BRITISH JOURNAL OF CANCER

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

STAT3 Regulation of Glioblastoma Pathogenesis

(2009) Nuria la Iglesia et al.   CURRENT MOLECULAR MEDICINE

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells

(2009) Maureen M. Sherry et al.   STEM CELLS

Deregulation of a STAT3-Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness

(2008) N. de la Iglesia et al.   JOURNAL OF NEUROSCIENCE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE